Category: Latest News
-
Lyft and Waymo to Launch Self-Driving Rides in Nashville in 2026
Lyft Inc. (NASDAQ:LYFT) and Waymo have joined forces to introduce autonomous ride-hailing in Nashville in 2026, the companies announced in a press release. The partnership will leverage Lyft’s Flexdrive subsidiary to manage Waymo’s autonomous fleet, covering vehicle maintenance, infrastructure, and depot operations. Initially, passengers will book rides through the Waymo app, with plans to integrate…
-
Oruka Therapeutics Shares Jump 20% on Strong Phase 1 ORKA-001 Data
Oruka Therapeutics (NASDAQ:ORKA) saw its stock soar 20% on Tuesday following the release of promising interim results from its Phase 1 trial of ORKA-001, a long-acting IL-23p19 antibody for treating plaque psoriasis. The company reported that ORKA-001 demonstrated an approximate half-life of 100 days, more than three times longer than that of risankizumab, a competitor.…
-
Roivant Shares Jump on Positive Phase 3 Data for Dermatomyositis Therapy
Shares of Roivant Sciences (NASDAQ:ROIV) climbed 9% after the company, together with partner Priovant Therapeutics, reported encouraging Phase 3 results for brepocitinib in patients with dermatomyositis, a rare autoimmune disorder. The once-daily oral brepocitinib 30 mg showed statistically significant and clinically meaningful improvements versus placebo across the primary endpoint and all nine key secondary endpoints.…
-
Paramount Shares Drop Following Rithm Capital Acquisition Announcement
Paramount Group, Inc. (NYSE:PGRE) saw its stock fall sharply, tumbling 12% after revealing a definitive agreement to be acquired by Rithm Capital Corp. (NYSE:RITM) in an all-cash deal valued at around $1.6 billion. Under the terms, Rithm will purchase all outstanding Paramount shares at $6.60 per fully diluted share, representing a notable discount from the…
-
Regeneron’s Garetosmab Achieves Over 90% Reduction in Bone Lesions in FOP Study
Regeneron (NASDAQ:REGN) reported positive results from its Phase 3 Optima trial evaluating garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), showing significant reductions in new bone formation. At the 56-week assessment, both dose levels outperformed placebo substantially. Patients receiving 3 mg/kg experienced a 94% decrease in new bone lesions, while those on the 10 mg/kg…
-
General Mills Tops Q1 Earnings Forecast Despite Sales Drop
General Mills, Inc. (NYSE:GIS) posted first-quarter fiscal 2026 results on Wednesday, surpassing analyst earnings expectations even as sales declined, and reaffirmed its full-year guidance. The company reported adjusted earnings of $0.86 per share, above the $0.81 consensus estimate, despite a 7% drop in net sales to $4.5 billion. Quarterly revenue of $4.52 billion met analyst…
-
New Fortress Energy Shares Surge on Long-Term Puerto Rico Gas Deal
Shares of New Fortress Energy Inc. (NASDAQ:NFE) jumped 23% in pre-market trading Wednesday following the announcement of a major long-term gas supply agreement with the Puerto Rican government. The company reached terms with Puerto Rico’s Third-Party Procurement Office and Public-Private Partnerships Authority for a seven-year liquefied natural gas (LNG) supply contract. The agreement is now…
-
UBS Predicts Silver Could Hit Record High as Investors Flock to Precious Metals
Silver has jumped to $42 an ounce, its highest level in 14 years, fueled by record-breaking gold prices and strong investment demand. Following this surge, UBS has upgraded its forecasts for the metal, projecting that silver could reach all-time highs within the next year. The bank now expects silver to trade at $44 an ounce…
-
Manchester United Shares Drop After Sixth Consecutive Annual Loss, Issues Soft Revenue Outlook
Manchester United (NYSE:MANU) on Wednesday revealed its sixth straight annual net loss, coupled with expectations of lower revenue in the current fiscal year, sending shares tumbling nearly 8% in premarket trading. The Premier League club reported a net loss of £33 million ($45 million) for the year ending June 30, an improvement from the £113.2…
-
Gemini Space Station Loses Steam After IPO as Investors Question Valuation
Shares of Gemini Space Station (NASDAQ:GEMI), the cryptocurrency exchange founded by Cameron and Tyler Winklevoss, were up 0.2% in pre-market trading on Wednesday, September 17, 2025, after closing 13.5% lower the previous day at $28.13. Since going public last Friday, the stock has already fallen nearly 24%, erasing much of the initial excitement. In its…